KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Operating Margin (2016 - 2025)

Emergent BioSolutions' Operating Margin history spans 15 years, with the latest figure at 18.76% for Q4 2025.

  • For Q4 2025, Operating Margin fell 1388.0% year-over-year to 18.76%; the TTM value through Dec 2025 reached 13.47%, up 2643.0%, while the annual FY2025 figure was 13.47%, 2389.0% up from the prior year.
  • Operating Margin reached 18.76% in Q4 2025 per EBS's latest filing, down from 33.1% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 39.13% in Q4 2021 to a low of 407.0% in Q2 2024.
  • Average Operating Margin over 5 years is 31.78%, with a median of 10.25% recorded in 2021.
  • Peak YoY movement for Operating Margin: plummeted -32032bps in 2024, then skyrocketed 40814bps in 2025.
  • A 5-year view of Operating Margin shows it stood at 39.13% in 2021, then plummeted by -143bps to 16.75% in 2022, then grew by 5bps to 15.84% in 2023, then soared by 69bps to 4.88% in 2024, then crashed by -285bps to 18.76% in 2025.
  • Per Business Quant, the three most recent readings for EBS's Operating Margin are 18.76% (Q4 2025), 33.1% (Q3 2025), and 1.14% (Q2 2025).